Drafting Consumer Breach Notices — From a Litigation Perspective - Unauthorized Access Podcast
Landlord and Tenant Lease Risk Reduction for the Cannabis Industry
Insurtech Briefly Podcast: Licensing, Google and Lead Gens
Edible Bites Episode 7: Oregon Psilocybin Services Act, Measure 109 Overview and Licensure
PODCAST: GovCon Perspectives - Are You Interested in Investing in a Company With a Federal Firearms License (FFL)?
Bill on Bankruptcy: Supreme Court Cases Will Have Wide Impact
Polsinelli Podcast - Avoiding Professional Liability
Patent Series: Protecting inventions
License to travel: how regulation is benefiting business abroad
Uncertainty Surrounds Illinois’s Nationally-Watched Collaborative Legislation On Fracking
Harlem Shake's Copyright Issues
Craft Beer Boom in Michigan
Unlocking Your Cell Phone Is Now Illegal, but Not for Long
Weekly Brief: New DOJ Tact Pushes Bank Subsidiaries To Admit Guilt
Looking Ahead to Washington State’s Legalized Marijuana Marketplace
On Feb 12, 2023, Biocon Biologics announced that the FDA issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for its biosimilar referencing AVASTIN (bevacizumab), previously submitted by...more
Key Takeaways: The draft guidance represents the first-ever specific expectation by FDA that sponsors develop a diversity plan for trials. FDA’s recommendations come as part of increasing interest in ensuring clinical...more
The FDA recently requested comment on its draft guidance for implementation of the “deemed to be a license” provision as described in section 7002(e) of the Biologics Price Competition and Innovation Act of 2009 (“BPCI Act”)....more